BRUSSELS (BELGIUM) – In a bid to address the short-term needs of European patients, the EU executives said on Wednesday that it had agreed to buy limited number of COVID-19 medicine remdesivir from Gilead of the US.
This is the only drug so far approved by the EU to treat patients with acute symptoms of coronavirus. However, all supplies have been purchased by the US.
In a statement, the EU Commission said it would pay 63 million euros (57.06 million pounds) to doses to treat as many as 30,000 patients.
In June, the US had inked an agreement with Gilead for 500,000 doses, accounting for most of the firm’s output through September.
The EU Commission said it was seeking to procure new doses from October.
(Photos syndicated via Reuters)
This story has been edited by BH staff and is published from a syndicated field
